Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents
Aim: To investigate whether there is any pharmacokinetic rationale for the common practice of administering vincristine to adolescents at relatively lower doses than those to younger children. Methods: A total of 98 children, aged 1.3-17.3 y, with acute lymphoblastic leukaemia (ALL) were studied on day I of induction therapy. Plasma samples were drawn before and 10, 30, 360 and 1380 min after inje